This Week in Infectious Disease — Jul 10, 2026

Welcome to This Week in Infectious Disease. This week we're covering eight notable papers spanning antimicrobial resistance strategies, viral prevention and treatment optimization, and clinical outcomes in vulnerable global populations. Let's dive in.

We begin this week with critical advancements in managing drug-resistant bacterial infections, a major focus of modern infectious disease practice. In a major step forward for antimicrobial stewardship, the ASTARTÉ trial, published in The Lancet, evaluated whether the narrow-spectrum beta-lactam temocillin could serve as a carbapenem-sparing alternative for bloodstream infections [1]. This multicenter, phase three, open-label, non-inferiority, randomized clinical trial was conducted across twenty-nine hospitals in Spain and enrolled adults with monomicrobial bacteremia caused by third-generation cephalosporin-resistant Enterobacterales. Patients were randomized to receive either intravenous temocillin at two grams every eight hours or a standard carbapenem regimen of meropenem or ertapenem for at least four days. Among the three hundred twenty-eight patients analyzed in the modified intention-to-treat population, clinical success at day twenty-eight was achieved in seventy-four percent of the temocillin group compared to seventy-three percent of the carbapenem group. This small difference met the pre-specified ten percent non-inferiority margin, confirming that temocillin is a highly effective alternative. Additionally, serious adverse events were slightly lower in the temocillin group, occurring in nineteen percent of patients compared to twenty-four percent in the carbapenem group. These findings provide robust clinical evidence supporting the routine use of temocillin to treat these resistant bloodstream infections, helping to preserve carbapenems and reduce broader selective pressure.

While temocillin represents a valuable narrow-spectrum option, managing resistance to our newest broad-spectrum agents remains an ongoing battle. A study published in Antimicrobial Agents and Chemotherapy shed light on the complex molecular mechanisms driving resistance to cefiderocol, a novel siderophore cephalosporin [8]. Researchers analyzed one hundred three clinical strains collected from sixty-one French hospitals between 2021 and 2024, all displaying cefiderocol minimum inhibitory concentrations greater than two milligrams per liter. The investigators discovered that resistance was highly multifactorial and polyclonal. Acquired beta-lactamases were detected in nearly seventy-three percent of the strains, with approximately forty percent carrying carbapenemases, primarily NDM-1, and nearly thirty-nine percent carrying extended-spectrum beta-lactamases such as VEB-1 and VEB-9. When the researchers cloned these beta-lactamases into a laboratory strain, they observed up to a remarkable one hundred twenty-eight-fold increase in cefiderocol minimum inhibitory concentrations. Furthermore, resistance was driven by specific mutations in the Pseudomonas-derived cephalosporinase enzyme and alterations in siderophore transporters or regulators, including a frameshift mutation in the PirR gene. This diverse array of resistance mechanisms, especially the high prevalence of NDM-producing strains, highlights the critical need for routine susceptibility testing and suggests that clinicians should exercise extreme caution when considering cefiderocol for infections where metallo-beta-lactamases are suspected.

Moving on to viral pathogens, our next theme explores clinical insights into viral prevention and treatment. We start with a virologic analysis of the phase three REDPINE trial, published in Antimicrobial Agents and Chemotherapy, which evaluated the use of remdesivir in patients with impaired kidney function hospitalized with COVID-19 [2]. This analysis focused on a cohort of two hundred forty-three treated participants, which included forty-two solid organ transplant recipients on active immunosuppressive therapy. While remdesivir therapy overall led to significantly greater reductions in viral load on days five and seven compared to placebo, the solid organ transplant recipients experienced significantly slower viral clearance on days five, seven, and fourteen compared to patients without transplants. Mathematical modeling of viral kinetics in kidney transplant recipients predicted that extending the remdesivir treatment duration from five days to ten days could accelerate the time to viral clearance by more than thirteen days. Additionally, the researchers identified the post-treatment emergence of specific mutations in the viral polymerase gene, such as E136V, M794I, and C799F, which conferred low-level reduced susceptibility to remdesivir. Three of the four patients who developed these mutations were solid organ transplant recipients. These findings suggest that the standard five-day course of remdesivir may be insufficient for highly immunosuppressed patients, and extending therapy could improve viral clearance and potentially prevent the emergence of resistant strains.

In the realm of viral prevention, a common clinical question is whether the use of pre-vaccination pain relievers compromises the immune response. A study published in The Journal of Infectious Diseases addressed this directly by evaluating the impact of pre-vaccination analgesics on influenza vaccine immunogenicity and effectiveness [3]. Utilizing data from the PAIVED trial, a randomized study conducted among United States military healthcare beneficiaries, researchers analyzed over six hundred participants who provided pre- and post-vaccination blood samples, and over ten thousand participants who underwent weekly influenza-like illness surveillance. Approximately ten percent of participants reported using analgesics, such as acetaminophen or nonsteroidal anti-inflammatory drugs, within twenty-four hours before receiving their influenza vaccine. The multivariable analyses revealed no significant association between pre-vaccination analgesic use and changes in antibody geometric mean titers. Furthermore, there was no association between analgesic use and the incidence of influenza-like illness or the overall odds of laboratory-confirmed influenza infection. While a modest initial association was observed between acetaminophen use and increased seroconversion to influenza A H3N2, this did not remain significant in sensitivity analyses adjusting for multiple comparisons. These reassuring results suggest that clinicians can confidently advise patients that taking analgesics shortly before vaccination to prevent local or systemic side effects does not reduce the vaccine's protective benefits.

Staying with influenza prevention, another study in The Journal of Infectious Diseases explored the protective role of neuraminidase-inhibiting antibodies, which are often overlooked because current vaccines are standardized to induce hemagglutinin-inhibiting antibodies [5]. Utilizing sera from a prospective vaccine effectiveness study among healthcare personnel in Israel during the 2017 to 2018 influenza season, researchers evaluated the protective effects of these neuraminidase antibodies against influenza B viruses. While vaccination did not consistently elicit a significant rise in neuraminidase-inhibiting titers against the vaccine strain, baseline neuraminidase titers were one point five times higher against the vaccine strain and two point five times higher against the circulating B/Phuket strain in vaccinated versus unvaccinated individuals. Most importantly, the study demonstrated that each two-fold rise in neuraminidase-inhibiting antibody titers was associated with a forty-two percent reduction in the hazard of symptomatic infection against B/Phuket and a twenty-three percent reduction against B/Brisbane, even after adjusting for hemagglutinin-inhibiting titers. This finding establishes neuraminidase-inhibiting antibodies as a strong, independent correlate of protection against influenza B, suggesting that standardizing and optimizing the neuraminidase content in future influenza vaccines could provide much broader and more robust clinical protection.

To round out our viral therapeutics discussion, a review published in PLoS Pathogens highlights the clinical evolution and mechanism of action of HIV capsid inhibitors, with a particular focus on lenacapavir [4]. Unlike conventional antiretrovirals that target viral enzymes, capsid inhibitors bind to highly conserved structural interfaces on the HIV capsid, disrupting multiple essential steps of viral replication, including capsid assembly, disassembly, nuclear import, and integration. This novel mechanism makes them exceptionally potent and valuable, particularly for long-acting pre-exposure prophylaxis and the treatment of multi-drug resistant HIV. However, the review cautions that the long-term success of this drug class depends on understanding and monitoring resistance-associated mutations. It highlights the need for global surveillance of capsid polymorphisms and discusses the significant implementation challenges, such as drug accessibility and cost-effectiveness in resource-limited settings, which must be overcome to fully realize the transformative potential of capsid inhibitors in the global fight against HIV.

Our final theme turns to global infectious disease outcomes in vulnerable populations, starting with pediatric respiratory syncytial virus, or RSV. In The Lancet Global Health, researchers presented a twenty-five-year retrospective cohort study analyzing pediatric surveillance data from Kilifi County Hospital in rural Kenya [6]. Out of more than seventy-five thousand infant admissions between 2001 and 2025, over nineteen thousand met the clinical criteria for pneumonia, and two thousand seven hundred forty-five of these infants were confirmed to have RSV. The in-hospital mortality rate among post-neonatal infants admitted with RSV pneumonia was two point four percent, with over three-quarters of these deaths occurring within seven days of admission. Alarmingly, the study found no evidence of a sustained decline in RSV-associated in-hospital mortality or improvement in infant nutritional status over the entire twenty-five-year study period. The strongest independent predictors of mortality were congenital heart disease, severe undernutrition, and hypoxemia. Notably, seventy percent of the infants who died in the hospital had a mid-upper arm circumference below the severe acute malnutrition threshold. These findings underscore that pediatric RSV mortality in low-resource settings is heavily compounded by chronic nutritional deficits, emphasizing that reducing mortality will require not only viral prevention but also targeted nutritional interventions.

Another critical area of global health is the safety of essential therapeutics during pregnancy and lactation. Pretomanid is a vital component of the World Health Organization-recommended regimen for multidrug-resistant pulmonary tuberculosis, yet it is currently not recommended during pregnancy or breastfeeding due to a lack of clinical data. A study in Antimicrobial Agents and Chemotherapy sought to address this gap by evaluating the nonclinical reproductive toxicology profile of pretomanid alongside the clinical outcomes of eleven women exposed to the drug during pregnancy [7]. In animal models, pretomanid showed no adverse maternal or developmental effects in rats or rabbits at exposures up to twice the clinical dose during organogenesis, and no adverse effects on offspring fertility. While higher doses in rats did result in some maternal toxicity and lower pup weights, these occurred at more than four times the standard clinical exposure. Among the eleven clinical pregnancies documented, five resulted in healthy babies, five underwent elective abortions, and one experienced a spontaneous abortion. While these clinical numbers are small, the reassuring nonclinical safety profile and initial clinical outcomes support the safety of further evaluating pretomanid in pregnant and lactating women, offering hope for safer, more effective tuberculosis regimens in this vulnerable population.

If you only have time for one paper this week, make it the ASTARTÉ trial published in The Lancet [1]. This multicenter, randomized controlled trial provides high-quality, practice-changing evidence that temocillin is a highly effective, safe, and non-inferior carbapenem-sparing alternative for treating bacteremia caused by third-generation cephalosporin-resistant Enterobacterales, offering clinicians a powerful tool to improve antibiotic stewardship.

Here are the key takeaways from this week in Infectious Disease: First, temocillin is non-inferior to carbapenems for targeted treatment of third-generation cephalosporin-resistant Enterobacterales bacteremia, providing a crucial narrow-spectrum option for antimicrobial stewardship. Second, cefiderocol resistance is highly complex and multifactorial, driven by acquired beta-lactamases like NDM-1 and impaired siderophore uptake, necessitating routine susceptibility testing and cautious use. Third, solid organ transplant recipients hospitalized with COVID-19 show delayed viral clearance with standard five-day remdesivir therapy, suggesting a potential benefit from an extended ten-day course. Fourth, taking acetaminophen or nonsteroidal anti-inflammatory drugs within twenty-four hours before influenza vaccination does not impair antibody responses or clinical vaccine effectiveness. And finally, severe undernutrition and congenital heart disease remain the leading predictors of RSV-related mortality in infants in low-resource settings, with no mortality decline observed over the past twenty-five years.

That's your roundup for This Week in Infectious Disease. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.